Abstract Number: PB0028
Meeting: ISTH 2020 Congress
Background: Matrix metalloproteinase-12 (MMP-12) can lead to plaque destabilization and rupture of atherosclerotic plaques. Upregulation of stromal cell-derived factor (SDF1) has been shown to play a role in various cardiovascular processes.
Aims: The goal of this study was to determine SDF1 and MMP12 to evaluate cardiovascular risk and atherotrombotic events in patients with cardiovascular risk factors.
Methods: We enrolled 298 patients, median age: 66 year-old (range 45-90 years old), 70.8% male. Cardiovascular risk factors, presence of atherosclerotic plaques by arterial ultrasound (carotid, femoral and aorta), and previous cardiovascular events: heart attack, stroke, peripheral artery disease (PAD) and nephropathy were recorded. Patients were classified in two groups according to the presence or absence of previous cardiovascular events.
Serum MMP12 and SDF1 were determined by ELISA (LSBio and R&D respectively) and CRP on automated analyzer. Firstly, we evaluated the correlation of classical inflammatory biomarkers and new biomarkers: MMP12 and SDF1. Thereafter, we established the association between this parameters and cardiovascular events.
Medical ethics committee approved the study and all patients signed informed consent.
Results: We found a correlation between SDF1 and PCR (r=0.42, p< 0.001) and MMP12 and CRP (r= 0.31; p< 0.001). Compared with asymptomatic subjects (that includes patients with and without atherosclerotic plaques), those patients who had a previous event had higher levels of SDF1 (2706 pg/mL vs 2309 pg/mL, p=0.009) and MMP12 (501 pg/mL vs 357 pg/mL, p=0.016). Association was detected between SDF1 and stroke (p=0.042) and with nephropathy (p=0.004) and between MMP12 and nephropathy (p=0.05), after adjusting by age and sex. Finally, those patients who had plaques in three vascular territories at the same time presented higher levels of SDF1 (2364 pg/mL vs 2538 pg/mL, p=0,025), independently of age and sex.
Conclusions: SDF1 and MMP12 were associated with clinical atherosclerosis, thus, offering additional information on top of classical inflammatory biomarkers.
To cite this abstract in AMA style:Marcos Jubilar M, Pastrana JC, Orbe J, Roncal C, Rodriguez JA, Fernández-Montero A, Rodil R, Colina I, Páramo JA. Association of MMP-12 and SDF1 with Symptomatic and Asymptomatic Atherosclerosis [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/association-of-mmp-12-and-sdf1-with-symptomatic-and-asymptomatic-atherosclerosis/. Accessed July 1, 2022.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/association-of-mmp-12-and-sdf1-with-symptomatic-and-asymptomatic-atherosclerosis/